Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.00 USD

74.00
173,732

+0.70 (0.96%)

Updated Jul 18, 2024 10:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand

by Zacks Equity Research

Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.

The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx

Sheraz Mian headshot

Top Analyst Reports for Coca-Cola, Merck & Royal Dutch Shell

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola (KO), Merck (MRK), and Royal Dutch Shell (RDS.A).

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $62.52, marking a +0.92% move from the previous day.

Regeneron (REGN) Releases Initial Data on Cocktail for COVID-19

by Zacks Equity Research

Regeneron (REGN) reports positive initial data on its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.

FATE Surges More Than 152% in Three Months: Here's Why?

by Zacks Equity Research

FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $58.49 in the latest trading session, marking a -1% move from the prior day.

Here's Why Lilly (LLY) Has Outperformed the Industry This Year

by Zacks Equity Research

Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make antibodies to treat COVID-19.

The Zacks Analyst Blog Highlights: PayPal, Shopify, BP p.l.c., Gilead Sciences and Southern Co

by Zacks Equity Research

The Zacks Analyst Blog Highlights: PayPal, Shopify, BP p.l.c., Gilead Sciences and Southern Co

Sheraz Mian headshot

Top Research Reports for PayPal, Shopify & BP

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings (PYPL), Shopify (SHOP) and BP p.l.c. (BP).

Company News for Dec 17, 2020

by Zacks Equity Research

Companies In The News Are: GOOGL, LUV, TLRY, APHA, GLPG, GILD.

Gilead's (GILD) CAR T Cell Therapy Tecartus Wins EC Nod

by Zacks Equity Research

Gilead (GILD) company, Kite, gets conditional marketing authorization for CAR T cell therapy, Tecartus.

Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal

by Zacks Equity Research

Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.

Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More

by Zacks Equity Research

Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.

Lilly (LLY) Stock Up on Raised 2020 View, Upbeat 2021 Guidance

by Zacks Equity Research

Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $59.84, moving -1.51% from the previous trading session.

Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV

by Zacks Equity Research

Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.

Gilead (GILD) to Buy MYR GmbH for EUR1.15 Billion in Cash

by Zacks Equity Research

Gilead (GILD) will purchase MYR GmbH for EUR1.15 billion and add HDV treatment Hepcludex to its portfolio.

Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $60.82 in the latest trading session, marking a -0.57% move from the prior day.

Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH

by Zacks Equity Research

Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.

Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy

by Zacks Equity Research

Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop an oligonucleotide therapy for NASH. Shares rise.

Gilead's (GILD) Kite Presents Data on CAR T Cell Therapy at ASH

by Zacks Equity Research

Gilead (GILD) posts positive data on CAR T Cell Therapy Yescarta from multiple studies at ASH.

Lilly (LLY)/UnitedHealth Launch COVID-19 Study on Bamlanivimab

by Zacks Equity Research

The pragmatic study by Lilly (LLY) and UnitedHealth Group (UNH) is set to evaluate bamlanivimab in high-risk symptomatic patients who test positive for COVID-19

Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US

by Zacks Equity Research

With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).

Ritujay Ghosh headshot

COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap

by Ritujay Ghosh

Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.